Junshi Biosciences Adds ESG Focus and Revamps Pay Policies

Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an update.

Shanghai Junshi Biosciences has upgraded its board-level strategic committee into a Strategic and ESG Committee, expanding its remit to cover environmental, social and governance issues alongside long-term strategy and major investments. The move is aimed at strengthening the company’s ESG management and sustainable development capabilities without changing the committee’s composition or term.

The company has also drawn up new remuneration policies for directors and senior management to build a more effective incentive and restraint mechanism. These policies, designed to boost leadership motivation, innovation and operational efficiency, have been approved by the board and will be put to shareholders for approval at an upcoming general meeting.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$22.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in the People’s Republic of China and listed in Hong Kong and Shanghai. The company focuses on developing and commercializing innovative therapies and operates within a governance framework overseen by a board comprising executive, non-executive and independent directors.

Average Trading Volume: 3,152,085

Technical Sentiment Signal: Sell

Current Market Cap: HK$32.33B

See more insights into 1877 stock on TipRanks’ Stock Analysis page.